Crucell Secures Euro 2 Million Grant for Malaria Collaboration from Dutch Ministry of Economic Affairs
23. Dezember 2004 02:09 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Dec. 23, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (Nasdaq:CRXL) announced today that it has received a grant of up to Euro 2 Million from...
Crucell Announces Second PER.C6(R) License Agreement with Chiron
22. Dezember 2004 02:07 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Dec. 22, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (Nasdaq:CRXL) today announced that it has signed a second PER.C6(R) license agreement...
CEVEC Acknowledges Crucell Claims in Patent Infringement Hearing
16. Dezember 2004 02:10 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Dec. 16, 2004 (PRIMEZONE) -- In the patent infringement action initiated by Crucell (Nasdaq:CRXL) against CEVEC Pharmaceuticals GmbH, the German Dusseldorf District Court...
Crucell Announces Milestone Achievement in Merck's PER.C6(R)-related Investigational HIV Vaccine Program
15. Dezember 2004 08:20 ET
|
Crucell N.V.
LEIDEN, Netherlands, Dec. 15, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that Merck & Co., Inc. (NYSE:MRK) has met a clinical...
Crucell Candidate for Amsterdam Midkap Index on Euronext
30. November 2004 10:50 ET
|
Crucell N.V.
LEIDEN, Netherlands, Nov. 30, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has been selected by Euronext Indices B.V. (Euronext)...
Graham Dixon joins Galapagos as Chief Scientific Officer
30. November 2004 02:06 ET
|
Crucell N.V.
MECHELEN, Belgium and LEIDEN, The Netherlands, Nov. 30, 2004 (PRIMEZONE) -- Galapagos announced today that Graham Dixon has been appointed Chief Scientific Officer (CSO). Dr. Dixon will be...
Crucell Announces PER.C6 Licensing Agreement with Edwards Lifesciences
24. November 2004 02:33 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Nov. 24, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a PER.C6(r) research license agreement...
Crucell and DSM Announce PER.C6 Licensing Agreement with Micromet for Monoclonal Antibody Production
19. November 2004 02:08 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Nov. 19, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that they...
Celgene and Galapagos Enter Target Discovery Collaboration
18. November 2004 07:10 ET
|
Crucell N.V.
WARREN, N.J. and MECHELEN, Belgium and LEIDEN, The Netherlands (PRIMEZONE) -- Celgene (Nasdaq:CELG), a leading global biopharmaceutical company with focus on the discovery, development and...
Crucell Discovers and Validates Human Monoclonal Antibody Product that Protects Against Rabies in Collaboration with CDC and TJU
16. November 2004 11:56 ET
|
Crucell N.V.
LEIDEN, Netherlands, Nov. 16, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today the discovery and preclinical validation of an effective...